MILAGE
Tadalafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.
- Categories : Benign Prostatic Hyperplasia Agents
- Share Now :
Tadalafil 5/10/20 mg Tablets
MILAGE 5/10/20
COMPOSITION
Milage 5
Each film coated tablet contains
Tadalafil 5 mg
Milage 10
Each film coated tablet contains
Tadalafil 10 mg
Milage 20
Each film coated tablet contains
Tadalafil 20 mg
SUMMARY
Tadalafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.
DOSAGE FORM: Tablets
PHARMACOLOGICAL CATEGORY: Phosphodiesterase type 5 inhibitor (cGMP-specific)
THERAPEUTIC CATEGORY: Urologicals, Drugs used in erectile dysfunction
INDICATIONS AND DOSAGE REGIMEN
MILAGE 5
- For the treatment of erectile dysfunction in adult males (daily use), taken once a day at the same time each day.
- To treat the signs and symptoms of Benign Prostatic Hyperplasia (BPH) taken once a day at the same time each day.
MILAGE 10
- Treatment of erectile dysfunction in adult males (as needed), no more than once a day, taken 30 minutes before you think sexual activity may occur.
MILAGE 20
- Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity in adults. Two tablets taken at the same time each day. The doctor may adjust the dose as needed.
The dose must be as directed by the physician. It is recommended to be taken with or without food.
This medication should not be used in children as safety and efficacy has not been established.
METHOD OF ADMINISTRATION
Route of Administration: Oral
PREGNANCY AND LACTATION
Not recommended for use in pregnant and lactating women.
STORAGE AND HANDLING
Keep the medication stored at normal room temperature and out of reach of children.
Dispose unused medications and expired medications properly to avoid adverse effects.
CONTRAINDICATIONS
- Known hypersensitivity to Tadalafil or any other components of the formulation.
- Patients with myocardial infarction or stroke within the last 90 days.
- Patients with unstable angina or angina occurring during sexual intercourse.
- Patients with uncontrolled arrhythmias, hypotension (< 90/50mmHg), or uncontrolled hypertension.
- Patients who are using any form of organic nitrate.
- Co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat.
Related Products
